• Soleno Therapeutics Inc SLNO.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of nine analysts for the quarter was for a loss of 93 cents per share. Wall Street expected results to range from $-1.43 to -66 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Soleno Therapeutics Inc's reported EPS for the quarter was a loss of 95 cents​.

• The company reported a quarterly loss of $43.77 million.

• Soleno Therapeutics Inc shares had risen by 3.2% this quarter and gained 64.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 23.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Soleno Therapeutics Inc is $105.00

This summary was machine generated from LSEG data May 7 at 09:06 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)